PDF(Pubmed)
Abstract：
Background: Pathological progression from non-alcoholic fatty liver disease (NAFLD) to liver fibrosis (LF) to hepatocellular carcinoma (HCC) is a common dynamic state in many patients. Curcumin, a dietary supplement derived from the turmeric family, is expected to specifically inhibit the development of this progression. However, there is a lack of convincing evidence. Methods: The studies published until June 2023 were searched in PubMed, Web of Science, Embase, and the Cochrane Library databases. The SYstematic Review Center for Laboratory animal Experimentation (SYRCLE) approach was used to evaluate the certainty of evidence. StataSE (version 15.1) and Origin 2021 software programs were used to analyze the critical indicators. Results: Fifty-two studies involving 792 animals were included, and three disease models were reported. Curcumin demonstrates a significant improvement in key indicators across the stages of NAFLD, liver fibrosis, and HCC. We conducted a detailed analysis of common inflammatory markers IL-1β, IL-6, and TNF-α, which traverse the entire disease process. The research results reveal that curcumin effectively hinders disease progression at each stage by suppressing inflammation. Curcumin exerted hepatoprotective effects in the dose range from 100 to 400 mg/kg and treatment duration from 4 to 10 weeks. The mechanistic analysis reveals that curcumin primarily exerts its hepatoprotective effects by modulating multiple signaling pathways, including TLR4/NF-κB, Keap1/Nrf2, Bax/Bcl-2/Caspase 3, and TGF-β/Smad3. Conclusion: In summary, curcumin has shown promising therapeutic effects during the overall progression of NAFLD-LF-HCC. It inhibited the pathological progression by synergistic mechanisms related to multiple pathways, including anti-inflammatory, antioxidant, and apoptosis regulation.
摘要：
背景：从非酒精性脂肪性肝病（NAFLD）到肝纤维化（LF）再到肝细胞癌（HCC）的病理进展是许多患者的常见动态状态。姜黄素,来自姜黄家族的膳食补充剂，预计会特别抑制这种进展的发展。然而,缺乏令人信服的证据。方法：直到2023年6月发表的研究在PubMed上进行了搜索，WebofScience,Embase,和Cochrane图书馆数据库.使用SYstematic实验动物实验审查中心（SYRCLE）方法来评估证据的确定性。StataSE（15.1版）和Origin2021软件程序用于分析关键指标。结果：纳入52项研究，涉及792只动物，并报告了三种疾病模型。姜黄素显示出NAFLD各阶段关键指标的显着改善，肝纤维化,和HCC。我们对常见的炎症标志物IL-1β进行了详细分析，IL-6和TNF-α,贯穿整个疾病过程。研究结果表明，姜黄素通过抑制炎症在每个阶段有效地阻止疾病进展。姜黄素在100至400mg/kg的剂量范围内发挥肝脏保护作用，治疗持续时间为4至10周。机制分析表明，姜黄素主要通过调节多个信号通路发挥其保肝作用，包括TLR4/NF-κB，Keap1/Nrf2、Bax/Bcl-2/Caspase3和TGF-β/Smad3。结论：总之，姜黄素在NAFLD-LF-HCC的总体进展中显示出有希望的治疗效果。它通过与多个途径相关的协同机制抑制病理进展，包括消炎药,抗氧化剂，和凋亡调节。
